SCHEMBL4877576

SCHEMBL4877576

CC(C)CC(CN(O)C=O)C(=O)NC(C(=O)N1CCC(NC(=O)c2ccccc2)CC1)C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.48
CCR1 P32246 2/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
MMP1 P03956 3/20 0.42
TSHR P16473 1/20 0.41
ADAM17 P78536 1/20 0.41
PSMB11 A5LHX3 2/20 0.40
PSMA7 O14818 2/20 0.40
PSMB1 P20618 2/20 0.40
PSMA1 P25786 2/20 0.40
PSMA2 P25787 2/20 0.40
PSMA3 P25788 2/20 0.40
PSMA4 P25789 2/20 0.40
PSMB8 P28062 2/20 0.40
PSMB9 P28065 2/20 0.40
PSMA5 P28066 2/20 0.40
PSMB4 P28070 2/20 0.40
PSMB6 P28072 2/20 0.40
PSMB5 P28074 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4602951 1.00 NPSR1 (0.48) NPSR1CCR1MEN1KMT2AMMP1
SCHEMBL4886049 0.92 KMT2A (0.43) NPSR1MEN1KMT2ATSHRPOLB
SCHEMBL4886058 0.92 KMT2A (0.43) NPSR1MEN1KMT2ATSHRPOLB
SCHEMBL14066497 0.91 TSHR (0.44) NPSR1MEN1KMT2ATSHR
SCHEMBL4602320 0.90 NPSR1 (0.46) NPSR1CCR1MEN1KMT2AMMP2
SCHEMBL4602474 0.90 MMP1 (0.44) NPSR1CCR1MEN1KMT2AMMP1
SCHEMBL4887987 0.89 TSHR (0.41) NPSR1MEN1KMT2AMMP1TSHR
SCHEMBL4887977 0.89 TSHR (0.41) NPSR1MEN1KMT2AMMP1TSHR
SCHEMBL4877176 0.84 MMP2 (0.53) NPSR1CCR1MEN1KMT2AMMP1
SCHEMBL4603007 0.82 NPC1 (0.41) MEN1KMT2AMMP1TSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234333-A1 Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof KANG JAE-HOON 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234333-A1 Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof PDF, PEPD, DHPS NPSR1 3773/4885CCR1 4406/4885MEN1 3235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.